GRIK3

Across TCGA pan-cancer cohorts, GRIK3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GRIK3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GRIK3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRIK3 expression acts as an unfavorable survival marker, although some lineages such as LAML and COAD show a favorable association.

OV, LUAD, and UCEC are the cancer types where GRIK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.262	0.694	<.001	18	view →
LUAD	OS	Median	All	0.339	0.701	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LAML	DFS	Median	All	0.505	0.394	.007	4	view →
COAD	DFS	Median	All	0.834	0.436	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GRIK3–OV (OS)

Open the OV breakdown →